bronchoprotective

Ensifentrine (Ensifentrinum) is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.

Navafenterol saccharinate (AZD-887 saccharinate) is an inhaled, dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist that demonstrates high affinity for the human M3 receptor with a pIC50 of 9.5 and strong β2-adrenoceptor agonism with a pEC50 of 9.5. Navafenterol provides a sustained bronchoprotective and antisialagogue effects with a favorable cardiovascular safety profile, and serving as a valuable investigational compound for chronic obstructive pulmonary disease research.